A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 10 Nov 2017
At a glance
- Drugs Lanabecestat (Primary)
- Indications Alzheimer's disease
- Focus Biomarker; Registrational; Therapeutic Use
- Acronyms AMARANTH
- Sponsors Eli Lilly
- 18 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 08 Sep 2017 Planned primary completion date changed from 1 Aug 2019 to 1 Sep 2019.
- 25 Aug 2017 Planned End Date changed from 1 Aug 2019 to 1 Sep 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History